PNU-159682

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H35NO13
Molecular Weight	641.6192
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1OCCN2[C@H]3C[C@H](O[C@H]4C[C@@](O)(CC5=C4C(O)=C6C(=O)C7=C(OC)C=CC=C7C(=O)C6=C5O)C(=O)CO)O[C@@H](C)[C@H]3O[C@H]12

InChI

InChIKey=SLURUCSFDHKXFR-WWMWMSKMSA-N

InChI=1S/C32H35NO13/c1-13-29-16(33-7-8-43-31(42-3)30(33)46-29)9-20(44-13)45-18-11-32(40,19(35)12-34)10-15-22(18)28(39)24-23(26(15)37)25(36)14-5-4-6-17(41-2)21(14)27(24)38/h4-6,13,16,18,20,29-31,34,37,39-40H,7-12H2,1-3H3/t13-,16-,18-,20-,29+,30+,31-,32-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C32H35NO13
Molecular Weight	641.6192
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28068470 \| https://www.ncbi.nlm.nih.gov/pubmed/23154079	Interacts 323

PubMed

Title	Date	PubMed
Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.	2017-05	28258164
Virtual Cross-Linking of the Active Nemorubicin Metabolite PNU-159682 to Double-Stranded DNA.	2017-02-20	28068470
The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs.	2012-12-15	23154079
Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.	2005-02-15	15746066

Substance Class	Chemical Created by `admin` on `Wed Apr 02 12:20:18 GMT 2025` Edited by `admin` on `Wed Apr 02 12:20:18 GMT 2025`
Record UNII	CQ5A9ZNT7C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PNU 159682

Preferred Name

English

PNU-159682

Code

English

(8S,10S)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYDROXYACETYL)-1-METHOXY-10-(((1S,3R,4AS,9S,9AR,10AS)-OCTAHYDRO-9-METHOXY-1-METHYL-1H-PYRANO(4',3':4,5)OXAZOLO(2,3-C)(1,4)OXAZIN-3-YL)OXY)-5,12-NAPHTHACENEDIONE

Systematic Name

English

5,12-NAPHTHACENEDIONE, 7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(2-HYDROXYACETYL)-1-METHOXY-10-(((1S,3R,4AS,9S,9AR,10AS)-OCTAHYDRO-9-METHOXY-1-METHYL-1H-PYRANO(4',3':4,5)OXAZOLO(2,3-C)(1,4)OXAZIN-3-YL)OXY)-, (8S,10S)-

Systematic Name

English

Code System Code Type Description

FDA UNII

CQ5A9ZNT7C

Created by admin on Wed Apr 02 12:20:18 GMT 2025 , Edited by admin on Wed Apr 02 12:20:18 GMT 2025

PRIMARY

PUBCHEM

9874188

Created by admin on Wed Apr 02 12:20:18 GMT 2025 , Edited by admin on Wed Apr 02 12:20:18 GMT 2025

PRIMARY

SMS_ID

300000039898

Created by admin on Wed Apr 02 12:20:18 GMT 2025 , Edited by admin on Wed Apr 02 12:20:18 GMT 2025

PRIMARY

CAS

202350-68-3

Created by admin on Wed Apr 02 12:20:18 GMT 2025 , Edited by admin on Wed Apr 02 12:20:18 GMT 2025

PRIMARY

Related Record Type Details


					CQ5A9ZNT7C

PNU-159682

ACTIVE MOIETY

Comments:

If the target for the payload is in the cytoplasm e.g. tubulin for paclitaxel, the drug binds to its target in the cytoplasm and triggers apoptosis of the tumor cell. If the target is in the nucleus e.g. DNA intercalating agents like doxorubicin and PNU-159682, then the drug enters from the cytoplasm into the nucleus and intercalates with the genomic DNA resulting in apoptosis of the tumor cell.

Interaction Type:

IN-VIVO

Amount: